HIGHLIGHTS
- who: Michael J. Ausserlechner from the DepartmentMedical University Innsbruck, Innsbruck, Austria have published the article: X-linked inhibitor of apoptosis protein - a critical death resistance regulator and therapeutic target for personalized cancer therapy, in the Journal: (JOURNAL)
- future: This suggests that additional clinical studies are required to identify those cancer patient subgroups that benefit from XIAP-targeted therapy.
SUMMARY
Www.frontiersin.org July 2014 | Volume 4 | Article 197 | 1 XIAP as a therapeutical target in cancer therapy proteasomal degradation of bound proteins such as caspase-3 or the mitochondrial XIAP-inhibitor . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.